DelveInsight’s ‘Metastatic Melanoma Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline metastatic melanoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the metastatic melanoma pipeline domain.
For Metastatic Melanoma emerging drugs, the metastatic melanoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Metastatic Melanoma Pipeline Report
- Over 80+ metastatic melanoma pipeline therapies are in various stages of development, and their anticipated acceptance in the metastatic melanoma market would significantly increase market revenue.
- Leading metastatic melanoma companies such as Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, Biocad, Apexigen, Checkmate Pharmaceutical, Nektar therapeutics, HUYABIO International, LLC., IO Biotech, Bristol Myers Squibb, Karyopharm Therapeutics, Zucero Therapeutics, GlaxoSmithKline, Tesaro, Inc., Ultimovacs ASA, Eucure (Beijing) Biopharma Co., Ltd, Incyte Corporation, Philogen S.p.A., Ascentage Pharma, Exelixis/Ipsen, NovoCure Ltd., Hoffman-La-Roche, and others are developing new drugs for metastatic melanoma to improve the treatment landscape.
- Key metastatic melanoma pipeline therapies in various stages of development include EVX 01, IN 10018, AV MEL 1, Lifileucel, V937, NEO-PTC-01, Relatlimab, CyPep-1, HBI-8000, NKTR-214,CMP-001, IO102-IO103, EVX-01, APX005M, BCD-217, Dostarlimab, LXH254, Niraparib, BNT111, UV1, YH003, Retifanlimab, L19IL2+L19TNF, Pexa-Vec, APG-115, Cabozantinib, RO7247669, PV-10, BGB324, VB10.NEO, IMO-2125, ABI-007, HX008, BVD-523, IOV-4001, ST101, BGB-10188, DYP688, ATL001, PAC-1, IN10018, SX-682, TILT-123, PV-001-DC, CDX-301, TBX-3400, GR-MD-02, FHD-286, SD-101, MB-CART20.1, BMS-986249, SEA-CD40, LAG525, Fianlimab, ADP-TILIL7, Poke-101, and others.
- Promising metastatic melanoma therapies in the late stage of development (phase III) include HBI-8000 and IO102-IO103.
- NEO-PTC-01, TILT-123, AV MEL 1, and others are in the early stages of development for metastatic melanoma treatment.
Request a sample and discover the recent advances in metastatic melanoma treatment drugs @ Metastatic Melanoma Clinical Trial Outlook
Metastatic Melanoma Overview
Melanoma is the third most common cutaneous cancer, after basal cell carcinoma and squamous cell carcinoma. Melanoma is the fifth most common cancer in men and the sixth most common cancer in women. According to the American Cancer Society, the five-year metastatic melanoma survival rate for people diagnosed with melanoma that has spread to adjacent lymph nodes is 66%.
UV ray radiation is one of the leading causes of metastatic melanoma. Metastatic melanoma symptoms include fatigue, swollen or painful lymph nodes, weight loss, loss of appetite, difficulty breathing or a persistent cough, bone pain, migraines, seizures, and liver swelling. During the melanoma diagnosis process, the doctor will examine the patient’s skin. If they suspect the patient has skin cancer, they will need to perform a biopsy.
Find out more about metastatic melanoma treatment drugs @ Chemo Drugs for Metastatic Melanoma
Metastatic Melanoma Pipeline Analysis: Drug Profile
EVX 01: Evaxion Biotech
EVX-01 is a novel personalized cancer immunotherapy based on Evaxion’s PIONEERTM AI technology. EVX-01 is safe and shows promising early signs of clinically meaningful antitumor activity. Data showed that EVX-01 could elicit T-cell responses in a clinical setting where patients were also receiving standard immune therapy, such as anti-PD-1 treatment.
IN 10018: InxMed
IN10018 is a highly selective and potent adenosine triphosphate competitive FAK inhibitor, and InxMed has exclusive global development and commercialization rights. IN10018’s early clinical data demonstrated its safety and efficacy in various tumor types. The most recent research findings and preclinical data show that IN10018 can also be effective in combination therapies.
Metastatic Melanoma Pipeline Therapies and Key Companies
- HBI-8000: HUYABIO International, LLC
- IO102-IO103: IO Biotech
- CMP-001: Checkmate Pharmaceuticals
- EVX-01: Evaxion Biosciences
- APX005M: Apexigen, Inc.
- BCD-217: Biocad
- Pixatimod: Zucero Therapeutics
- Selinexor: Karyopharm Therapeutics
- Relatlimab: Bristol-Myers Squibb
- V937: Viralytics
- VB10.NEO: Nykode Therapeutics
Metastatic Melanoma Pipeline Therapeutics Assessment
- By Product Type
- Monotherapy
- Combination Therapy
- By Stage
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
-
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- By Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
Learn more about the novel and emerging metastatic melanoma pipeline therapies @ Metastatic Melanoma Clinical Trials
Scope of the Metastatic Melanoma Pipeline Report
- Coverage: Global
- Key Metastatic Melanoma Companies: Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, Biocad, Apexigen, Checkmate Pharmaceutical, Nektar therapeutics, HUYABIO International, LLC., IO Biotech, Bristol Myers Squibb, Karyopharm Therapeutics, Zucero Therapeutics, GlaxoSmithKline, Tesaro, Inc., Ultimovacs ASA, Eucure (Beijing) Biopharma Co., Ltd, Incyte Corporation, Philogen S.p.A., Ascentage Pharma, Exelixis/Ipsen, NovoCure Ltd., Hoffman-La-Roche, Provectus Biopharmaceuticals, BerGenBio ASA, Idera Pharmaceuticals, Celgene Corporation, Novartis, and others
- Key Metastatic Melanoma Pipeline Therapies: EVX 01, IN 10018, AV MEL 1, Lifileucel, V937, NEO-PTC-01, Relatlimab, CyPep-1, HBI-8000, NKTR-214, CMP-001, IO102-IO103, EVX-01, APX005M, BCD-217, Dostarlimab, LXH254, Niraparib, BNT111, UV1, YH003, Retifanlimab, L19IL2+L19TNF, Pexa-Vec, APG-115, Cabozantinib, RO7247669, PV-10, BGB324, VB10.NEO, IMO-2125, ABI-007, HX008, BVD-523, IOV-4001, ST101, BGB-10188, DYP688, ATL001, PAC-1, IN10018, SX-682, TILT-123, PV-001-DC, CDX-301, TBX-3400, GR-MD-02, FHD-286, SD-101, MB-CART20.1, BMS-986249, SEA-CD40, LAG525, Fianlimab, ADP-TILIL7, Poke-101, and others.
Dive deep into rich insights for new drugs for metastatic melanoma treatment, visit @ Metastatic Melanoma Treatment Drugs
Table of Contents
| 1. | Metastatic Melanoma Pipeline Report Introduction |
| 2. | Metastatic Melanoma Pipeline Report Executive Summary |
| 3. | Metastatic Melanoma Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Metastatic Melanoma Pipeline Therapeutics |
| 6. | Metastatic Melanoma Pipeline: Late Stage Products (Pre-registration) |
| 7. | Metastatic Melanoma Pipeline: Late Stage Products (Phase III) |
| 8. | Metastatic Melanoma Pipeline: Mid Stage Products (Phase II) |
| 9. | Metastatic Melanoma Pipeline: Early Stage Products (Phase I) |
| 10. | Metastatic Melanoma Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Metastatic Melanoma Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Metastatic Melanoma Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the metastatic melanoma pipeline therapeutics, reach out @ New Drugs for Metastatic Melanoma Treatment
Related Reports
Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic melanoma companies including Neon Therapeutics, BioNTech, Bristol-Myers Squibb, among others.
Metastatic Melanoma Epidemiology Forecast
Metastatic Melanoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted metastatic melanoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Metastatic Cutaneous Melanoma Pipeline
Metastatic Cutaneous Melanoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic cutaneous melanoma companies, including Neon Therapeutics, BioNTech, Bristol-Myers Squibb, among others.
Metastatic Cutaneous Melanoma Market
Metastatic Cutaneous Melanoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic cutaneous melanoma companies including Neon Therapeutics, BioNTech, Bristol-Myers Squibb, among others.
Refractory Metastatic Melanoma Pipeline
Refractory Metastatic Melanoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key refractory metastatic melanoma companies, including Idera Pharmaceuticals, BioNTech, Bristol-Myers Squibb, among others.
Refractory Metastatic Melanoma Market
Refractory Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key refractory metastatic melanoma companies including Idera Pharmaceuticals, BioNTech, Bristol-Myers Squibb, among others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |Spirometers Market | Hemodynamic Monitoring Systems Market | Deep Brain Stimulation Devices Market | Genital Herpes Market | Guillain-Barre Syndrome (GBS) Market | Hot Flashes Market | Human Immunodeficiency Virus Type-1 (HIV-1) Market | Hypertrophic Scar Market | Sinus Dilation Devices Market | Artificial Cornea and Corneal Implant Market |Peripheral Neuritis Market | Peripheral Vascular Devices Market | Diphtheria Market | Glioma Market | Fallopian Tube Cancer Market | Implantable Cardioverter Defibrillators (ICDs) Market | Smart Inhalers Market | Hemophilia A Market | Hemostasis Market | Peptic Ulcers Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187